Cancer Research UK

NCI, CRUK, Wellcome partner on cancer models to accelerate research

Monday, July 11, 2016

An international project to develop a large, globally accessible bank of new cancer cell culture models for the research community has launched. The National Cancer Institute (NCI), part of the NIH; Cancer Research U.K., London; the Wellcome Trust Sanger Institute, Cambridge, England; and the foundation Hubrecht Organoid Technology, Utrecht, Netherlands, are joining forces to develop the Human Cancer Models Initiative (HCMI), which will bring together expertise from around the world to make about 1,000 cancer cell models.

[Read More]

CRT, Merck to develop inhibitors for cancer and blood disorders

Tuesday, February 2, 2016

Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research U.K., has entered into a license agreement with MSD, known as Merck in the U.S. and Canada, to develop inhibitors of protein arginine methyltransferase 5 (PRMT5). These new drugs, which potentially have clinical applications in both cancer and non-cancer blood disorders, have been developed by the Australian Cooperative Research Center (CRC) for Cancer Therapeutics (CTx) with support from the Wellcome Trust and CRT.​

[Read More]